Literature DB >> 15179404

"Irinogenetics" and UGT1A: from genotypes to haplotypes.

Federico Innocenti1, Mark J Ratain.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15179404     DOI： 10.1016/j.clpt.2004.01.011

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  9 in total

1.  Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.

Authors:  Katerina Shulman; Ilana Cohen; Ofra Barnett-Griness; Abraham Kuten; Stephen B Gruber; Flavio Lejbkowicz; Gad Rennert
Journal:  Cancer       Date:  2011-02-01       Impact factor: 6.860

2.  A Pilot Study for Return of Individual Pharmacogenomic Results to Population-Based Cohort Study Participants.

Authors:  Kinuko Ohneda; Masahiro Hiratsuka; Hiroshi Kawame; Fuji Nagami; Yoichi Suzuki; Kichiya Suzuki; Akira Uruno; Mika Sakurai-Yageta; Yohei Hamanaka; Makiko Taira; Soichi Ogishima; Shinichi Kuriyama; Atsushi Hozawa; Hiroaki Tomita; Naoko Minegishi; Junichi Sugawara; Inaho Danjoh; Tomohiro Nakamura; Tomoko Kobayashi; Yumi Yamaguchi-Kabata; Shu Tadaka; Taku Obara; Eiji Hishimuma; Nariyasu Mano; Masaki Matsuura; Yuji Sato; Masateru Nakasone; Yohei Honkura; Jun Suzuki; Yukio Katori; Yoichi Kakuta; Atsushi Masamune; Yoko Aoki; Masaharu Nakayama; Shigeo Kure; Kengo Kinoshita; Nobuo Fuse; Masayuki Yamamoto
Journal:  JMA J       Date:  2022-03-11

Review 3.  Pharmacogenomics: candidate gene identification, functional validation and mechanisms.

Authors:  Liewei Wang; Richard M Weinshilboum
Journal:  Hum Mol Genet       Date:  2008-10-15       Impact factor: 6.150

4.  Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation.

Authors:  Caroline Raynal; Jean-Marc Pascussi; Géraldine Leguelinel; Cyril Breuker; Jovana Kantar; Benjamin Lallemant; Sylvain Poujol; Caroline Bonnans; Dominique Joubert; Frédéric Hollande; Serge Lumbroso; Jean-Paul Brouillet; Alexandre Evrard
Journal:  Mol Cancer       Date:  2010-03-02       Impact factor: 27.401

5.  UGT1A1, UGT1A6 and UGT1A7 genetic analysis: repercussion for irinotecan pharmacogenetics in the São Miguel Island Population (Azores, Portugal).

Authors:  Paula R Pacheco; Maria J Brilhante; Cristina Ballart; Francesc Sigalat; Helena Polena; Rita Cabral; Claudia C Branco; Luisa Mota-Vieira
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 6.  PharmGKB summary: very important pharmacogene information for UGT1A1.

Authors:  Julia M Barbarino; Cyrine E Haidar; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2014-03       Impact factor: 2.089

7.  Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.

Authors:  B Glimelius; H Garmo; A Berglund; L A Fredriksson; M Berglund; H Kohnke; P Byström; H Sørbye; M Wadelius
Journal:  Pharmacogenomics J       Date:  2010-02-23       Impact factor: 3.550

Review 8.  Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.

Authors:  Glenn E Palomaki; Linda A Bradley; Michael P Douglas; Katherine Kolor; W David Dotson
Journal:  Genet Med       Date:  2009-01       Impact factor: 8.822

9.  Distribution of uridine diphosphate glucuronosyltransferase 1A polymorphisms and their role in irinotecan-induced toxicity in patients with cancer.

Authors:  Yang Wang; Cuihua Yi; Yawei Wang; Hui Li; Bei Li; Dan Wang; Jintong Du; Lian Liu; Xiuwen Wang
Journal:  Oncol Lett       Date:  2017-09-14       Impact factor: 2.967
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.